This early phase I trial studies the feasibility of giving memantine for the reduction of cognitive impairment after radiation therapy in pediatric patients with central nervous system tumors. Memantine may reduce the effects of radiation therapy on memory and thinking.
PRIMARY OBJECTIVE: I. To evaluate the feasibility of twice daily memantine started before radiation therapy (RT) and one month after RT. SECONDARY OBJECTIVE: I. To evaluate the feasibility of twice daily (BID) memantine started before RT and continued 3 and 6 months after RT. EXPLORATORY OBJECTIVES: I. To evaluate the change in neurocognitive function (NCF) as found by formal neurocognitive testing between baseline and 12 months post-RT. II. To compare the change in NCF between baseline and the end of RT, 3,and 6 months after RT using both neuropsychological testing and the CogState exam. III. To evaluate changes in quantitative volumetric brain imaging using Neuroquant software analysis of magnetic resonance imaging (MRI) imaging before and 12 months after radiation. IV. To correlate cognitive changes detected by CogState composite score and formal neuropsychological testing. V. Disease-free (of primary tumor) and overall survival. OUTLINE: Patients receive memantine orally (PO) BID beginning at the time of study enrollment (no later than 1st day of RT) up to 6 months after completion of standard of care RT in the absence of unacceptable toxicity. Patients also complete CogState cognitive testing at baseline, at completion of RT, and at 3, 6, and 12 months after completion of RT. After completion of study, patients are followed up periodically.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
18
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Percentage of patients who attempt to take appropriate dose of memantine
The rate of feasibility (the percentage of patients who attempt to take at least 80% percent of their prescribed dose) will be calculated, along with corresponding 90% confidence intervals.
Time frame: At 1 month post-radiation therapy (RT)
Percentage of patients who attempt to take appropriate dose of memantine
The rate of feasibility (the percentage of patients who attempt to take at least 80% percent of their prescribed dose) will be calculated, along with corresponding 90% confidence intervals.
Time frame: At 3 and 6 months post-RT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.